Lindsay Androski's Insider Trades & SAST Disclosures
Lindsay Androski's most recent trade in Arbutus Biopharma Corp was a trade of 310,422 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lindsay Androski.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma Corp | Lindsay Androski | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 310,422 | 310,422 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharmaceuticals Inc | Lindsay Androski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 3,750 | 15,750 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Lindsay Androski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 3,750 | 3,750 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Androski Lindsay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 12,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Lindsay Androski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Lindsay Androski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 2,859 | 2,859 | - | - | Stock Options (Right to Buy) | |
| Eloxx Pharmaceuticals Inc | Lindsay Androski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 40,000 | 40,000 | - | - | Stock Options (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges